Selenium Not Linked to Recurrence of Non-Muscle-Invasive Bladder Cancer
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Oct. 18, 2023 -- For patients with non-muscle-invasive bladder cancer (NMIBC), selenium supplementation does not reduce the risk for recurrence, while vitamin E is associated with an increased risk for recurrence, according to a study published online Oct. 17 in JAMA Network Open.
Richard T. Bryan, Ph.D., from the University of Birmingham in the United Kingdom, and colleagues conducted a multicenter study involving patients with newly diagnosed NMIBC recruited from 10 secondary or tertiary care hospitals. Two hundred seventy patients were randomly assigned to selenium plus placebo, vitamin E plus placebo, selenium plus vitamin E, and placebo plus placebo in a double-blind manner (65, 71, 69, and 65 patients, respectively).
The median overall follow-up was 5.5 years; 84 percent were followed for more than five years. The median treatment duration was 1.5 years. Due to slow accrual, the study was halted. The researchers observed no difference in the recurrence-free interval (RFI) for selenium versus no selenium. A statistically significant detriment to RFI was seen for vitamin E versus no vitamin E. Significant differences were not observed with either supplement for the progression-free interval or overall survival time. After regression modeling to adjust for known prognostic factors, results were unchanged. A total of 1,957 adverse events were reported, including 85 serious; all appeared to be unrelated to trial treatment.
"These findings suggest that vitamin E supplementation may be harmful to patients with NMIBC, and elucidation of the underlying biology is required," the authors write.
One author disclosed ties to Cystotech.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Read this next
FDA Approves Anktiva for BCG-Unresponsive, Non-Muscle Invasive Bladder Cancer
FRIDAY, April 26, 2024 -- The U.S. Food and Drug Administration has approved Anktiva (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for th...
Gemcitabine, Cisplatin, Nivolumab Facilitate Bladder Sparing
WEDNESDAY, Oct. 4, 2023 -- For patients with muscle-invasive bladder cancer (MIBC), treatment with gemcitabine, cisplatin, plus nivolumab facilitates bladder sparing, according to...
Urine-Based DNA Methylation Test Can Detect Bladder Cancer
MONDAY, Aug. 21, 2023 -- A urine-based DNA methylation test can accurately detect bladder cancer in patients with hematuria, according to a study published online June 14 in The...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.